in patients who now achieve only partial treatment responses is a major challenge for biochemical, pharmacological, and clinical research of the treatment of mood disorders.
including improved treatment efficacy and progress with respect to side effects and toxicity. Although considerable advances have been made, with 18 antidepressant compounds being available and the impending release of two new antidepressant compounds in 1994, no one agent has demonstrated greater efficacy than another. Currently available studies suggest that only 21-42% of patients entered into treatment reach full recovery, while 20% of patients do not respond to available treatment but remain chronically depressed. Thus, the development of more efficacious agents that will produce complete remissions in patients who now achieve only partial treatment responses is a major challenge for biochemical, pharmacological, and clinical research of the treatment of mood disorders.
IndexingTerms:unipolar and bipolar depression/antidepressants
Clinical depressive disorders are common, and are associated with significant occupational and social impairment as well as with increased mortality in more severe cases. The diagnosis of a clinical depressive disorder may be difficult for several reasons:
it may be confused with the "depressed" or sad mood that normally accompanies specific life experiences such as losses or disappointments, or dismissed as a normal reaction to such losses and disappointments.
This difficulty can be overcome with knowledge of the speciuir symptoms and course of illness requirements for the diagnosis of clinical depression. Unlike many other ifinesses seen in medical practice, there is no medical laboratory test that has the necessary sensitivity and specificity to reliably diagnose the disorder. of the use of selective prescription medications (1). In addition, a brief reaction (bereavement) may initially (within the first 2 months) meet the criteria for a major depressive episode (1). Unipolar forms of primary mood disorders are divided into three groups: (a) Ml)D consists of one or more episodes of major depression with or without full recovery between these episodes (see Table 2 ). (b) Dysthymic disorder features a low-grade, more persistent (less episodic) depressed Table 3 ). (c) "Depression not otherwise specified" is a residual category reserved for patients with symptoms and signs of depression that do not meet the formal diagnostic criteria for either dysthymia or MDD.
Bipolar disorders are recurrent episodic conditions characterized by a history of at least one manic or hypomanic episode (see Table 4 ). Ninety-five percent of persons with bipolar disorder also have recurrent episodes of MDD. Bipolar disorders have also been grouped into three types: (a) Bipolar I disorder requires at least one manic episode along with (nearly always) MDD episodes. A manic episode consists of a distinct period of elevated or irritable mood, along with several symptoms such as grandiosity, decreased need for sleep, pressured sleep, and poor judgment (see Table 4 ). (b) Bipolar disorder "not otherwise specified" is a residual category that includes bipolar II disorder, a condition characterized by recurrent episodes of MDD along with hypomanic (but not full-blown manic) episodes, as well as other forms that do not meet formal criteria for bipolar I or cyclothymic disorder.
(c) Cyclothymic disorder is characterized by numerous hypomanic episodes and numerous periods of mild depressive symptoms insufficient in duration or severity to meet the criteria for major depressive episodes. Cyclothymic disorder is typically chronic, defined as lasting at least 2 years (1).
MDD may begin at any age, although it usually be- 
SIgnificant weight loss/gain.
Insomnla/hypersomnla. 5. Psychomotor agitation/retardation. 6. Fatigue (lossof energy). 7. Feelingsof worthlessness (guilt).
Impaired concentration (indecisiveness).

Recurrentthoughtsof death or suicide.
At least five of the above symptomsare present during the same period.At least depressedmood or loss of interest or pleasure must be present. Symptoms are present most of the day, nearly daily for at least 2 weeks.
Source: DSM-lll-R. Washington Studies also indicate that the treatment for MDD is more effective early in the episode before it becomes chronic (9-11). These findings suggest that early treatment is essential to reduce subsequent morbidity and mortality from clinical depression. The epidemiologic community samples include many mood-disordered persons who are neither seeking nor receiving treatment for their disorder, which suggests that these people are less ifi than those in treatment with mental health specialists.
Outcomes based on community samples are likely to provide a more optimistic view than the outcomes of primary care or psychiatric outpatient samples.
Physical complaints
are common during an episode of MDD. In one study, 23% of patients reported some days in which their health kept them in bed all or most of the day in the previous 2 weeks, compared with 5% for the general population; 38% of patients with MDD had some chronic activity restriction;
and 30% with depression reported decreased activity in the previous 2 weeks (12). Patients with MDD have more physical illnesses than do patients seen in primary care settings (13). Healthcare utilization is greater by persons in the community with MDD than by other patients in the general medical setting (14, 15) .
The mortality of patients with MDD is increased, generally secondary to suicide and accidents (16). A recent report indicated that patients with MDD admitted to nursing homes had a 59% greater death rate in the first year after admission than those without MDD (17). In the ECA study, patients with MDD and ages 55 or more had a mortality rate over the next 15 months four times greater than that of nondepressed agematched controls (1). In two recent studies, patients with high risk of coronary artery disease had significantly higher mortality in the presence of symptoms of depression (18, 19). Up to 15% of patients with MDD severe enough to require hospitalization eventually die by suicide (20, 21) . There are a number of common subgroups of MDD that vary greatly in severity; this defines a need for differences in clinical management strategies, which must be taken into account by psychiatric specialists. These variations are beyond the scope of this discussion but maybe accessed by referring to the Depression in Primary Care Clinical Practice Guidelines (1 ).
Epidemiology
"The point prevalence for MDD in western industrialized nations is 2.3 to 3.2% for men and 4.5 to 9.3% for women. The lifetime risk for MDD is 7-12% for men and 20-25% for women" (1). The lifetime psychiatric comorbidity rate for MDD can be as high as 43% (22), and the 1-month point prevalence for concurrent comorbidity is 8%. A major source of comorbidity with mood disorders is alcohol abuse-ranging from 10% to 67% of patients more frequently associated with mild but more chronic forms of clinical depression.
Although studies suggest an independent transmission of depression and alcoholism, the two conditions are often found in the same family (1).
Eleven studies, using structured psychiatric interviews and specific diagnostic criteria to determine the prevalence of MDD in primary care settings, showed a point prevalence of MDD ranging from 4.8% to 8.6% in outpatient settings and 14.6% of adult medical inpatients (1, 23). Several of the outpatient studies also found the occurrence of "depression not otherwise specified" disorders (mild or chronic depression) to be from 2% to 5% in outpatient populations.
Management and Treatment of Clinical Depression
It has been estimated that less than one-third of individuals with mood disorders receive treatment for this disorder (24 from normal human unhappiness that we all encounter and usually get over through time or psychological coping strategies, limit the frequency of the diagnosis in patients with the disorder. Attributing the illness to a cause such as a life stress (which, in fact, may frequently precede depression) and reasoning from this that the condition is not an ifiness but something an individual must "get over," limits diagnosis, as does the stigma of negative social attitudes implying weakness Monoamineoxidase inhibition lasts longer (7 days) than drug half-life. 'Includingpseudoephedrlne, phenylphrine, phenyipropanolamine, epinephnne, norepinephrine, and others. Source: ref. 
Use of Medication in Treatment of Depression
Antidepressant medications were discovered around 1952 and by 1965 were commonly used in the treatment of depression. Antidepressant medications have been classified into groups by both structure and mechanism, e.g., the early tricycic antidepressants (imipramine was the prototype) and the monoamine oxidase inhibitors (initially Marsilid but, subsequent to its removal from the market, other monoamine oxidase inhibitors), the more recent "atypical antidepressants," and, most recently, the serotonin-reuptake inhibitors (see Table 5 ). to develop more efficacious agents, which will achieve more complete remissions in patients with partial treatment responses. This is one of the important challenges for biochemical, pharmacological, and clinical research of the mood disorders.
